{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:26Z","timestamp":1772119586131,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA090628"],"award-info":[{"award-number":["CA090628"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Threshold Pharmaceuticals"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180821"],"award-info":[{"award-number":["U10CA180821"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180882"],"award-info":[{"award-number":["U10CA180882"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA232760"],"award-info":[{"award-number":["UG1CA232760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01090-w","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T08:02:55Z","timestamp":1614585775000},"page":"1072-1080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)"],"prefix":"10.1007","volume":"39","author":[{"given":"Nguyen H","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan R","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Mahipal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvin","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kabir","family":"Mody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Alberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"issue":"12","key":"1090_CR1","first-page":"1683","volume":"98121","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C et al (2017) The burden of primary liver Cancer and underlying Etiologies from 1990 to 2015 at the global, regional, and National Level. JAMA Oncology 98121(12):1683\u20131691","journal-title":"JAMA Oncology"},{"issue":"4","key":"1090_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"1","key":"1090_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334","journal-title":"Lancet Oncol"},{"issue":"20","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894\u20131905","journal-title":"N Engl J Med"},{"issue":"1","key":"1090_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY et al (2018) Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379(1):54\u201363","journal-title":"N Engl J Med"},{"issue":"3","key":"1090_CR6","first-page":"193","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL, KEYNOTE-240 investigators (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind. Phase III Trial J Clin Oncol 38(3):193\u2013202","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"2","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, REACH-2 study investigators (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282\u2013296","journal-title":"Lancet Oncol"},{"issue":"1","key":"1090_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1090_CR9","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386","journal-title":"Int J Cancer"},{"key":"1090_CR10","unstructured":"National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html [accessed November 20, 2020]"},{"issue":"14","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry M, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277\u20131290","journal-title":"N Engl J Med"},{"issue":"12","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Souli\u00e8res D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"23","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/1078-0432.CCR-06-0489","volume":"12","author":"TK Lee","year":"2006","unstructured":"Lee TK, Poon RT, Yuen AP, Ling MT, Wang XH, Wong YC et al (2006) Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res 12(23):6910\u20136919","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr (2008) The von Hippel\u2013Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865\u2013873","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10555-007-9065-z","volume":"26","author":"RJ Gillies","year":"2007","unstructured":"Gillies RJ, Gatenby RA (2007) Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 26(2):311\u2013317","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1090_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M H\u00f6ckel","year":"2001","unstructured":"H\u00f6ckel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4):266\u2013276","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8):583\u2013592","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1021\/jm701028q","volume":"51","author":"JX Duan","year":"2008","unstructured":"Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M (2008) Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51(8):2412\u20132420","journal-title":"J Med Chem"},{"key":"1090_CR19","doi-asserted-by":"publisher","unstructured":"Harms JK, Lee TW, Wang T, Lai A, Kee D, Chaplin JM, McIvor NP, Hunter FW, Macann AMJ, Wilson WR, Jamieson SMF (2019) Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models. Cells 8(7):717. https:\/\/doi.org\/10.3390\/cells8070717","DOI":"10.3390\/cells8070717"},{"issue":"1","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40880-018-0285-0","volume":"38","author":"Y Huang","year":"2018","unstructured":"Huang Y, Tian Y, Zhao Y, Xue C, Zhan J, Liu L, He X, Zhang L (2018) Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Cancer Commun 38(1):15","journal-title":"Cancer Commun"},{"issue":"3","key":"1090_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cam4.599","volume":"5","author":"V Liapis","year":"2016","unstructured":"Liapis V, Zinonos I, Labrinidis A, Hay S, Ponomarev V, Panagopoulos V, Zysk A, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A (2016) Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Med 5(3):534\u2013545","journal-title":"Cancer Med"},{"issue":"13","key":"1090_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","volume":"33","author":"MJ Borad","year":"2015","unstructured":"Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG, Rosen PJ, Ulrich B, Dragovich T, del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP (2015) Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic Cancer. J Clin Oncol 33(13):1475\u20131481","journal-title":"J Clin Oncol"},{"issue":"29","key":"1090_CR23","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","volume":"32","author":"SP Chawla","year":"2014","unstructured":"Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE et al (2014) Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol Off J Am Soc Clin Oncol 32(29):3299\u20133306","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1\u20132","key":"1090_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000327739","volume":"80","author":"KN Ganjoo","year":"2011","unstructured":"Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP (2011) A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology. 80(1\u20132):50\u201356","journal-title":"Oncology."},{"issue":"3","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","volume":"18","author":"JD Sun","year":"2012","unstructured":"Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP (2012) Selective tumor hypoxia targeting by hypoxia-activated Prodrug TH-302 inhibits tumor growth in preclinical models of Cancer. Clin Cancer Res 18(3):758\u2013770","journal-title":"Clin Cancer Res"},{"key":"1090_CR26","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"1090_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cmet.2012.10.017","volume":"16","author":"E Favaro","year":"2012","unstructured":"Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C et al (2012) Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 16(6):751\u2013764","journal-title":"Cell Metab"},{"issue":"3","key":"1090_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.freeradbiomed.2012.05.006","volume":"53","author":"C Riganti","year":"2012","unstructured":"Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D (2012) The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 53(3):421\u2013436","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"1090_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2049-3002-1-8","volume":"1","author":"S Ros","year":"2013","unstructured":"Ros S, Schulze A (2013) Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase\/fructose 2,6-bisphosphatases in cancer metabolism. Cancer Metab 1(1):8","journal-title":"Cancer Metab"},{"issue":"7","key":"1090_CR30","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1128\/MCB.24.7.2875-2889.2004","volume":"24","author":"JT Erler","year":"2004","unstructured":"Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, Dive C (2004) Hypoxia-mediated down-regulation of bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24(7):2875\u20132889","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1090_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1582-4934.2011.01337.x","volume":"14","author":"Y Wang","year":"2010","unstructured":"Wang Y, Ohh M (2010) Oxygen-mediated endocytosis in cancer. J Cell Mol Med 14(3):496\u2013503","journal-title":"J Cell Mol Med"},{"issue":"6","key":"1090_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393\u2013410","journal-title":"Nat Rev Cancer"},{"key":"1090_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","volume":"164","author":"C Wigerup","year":"2016","unstructured":"Wigerup C, P\u00e5hlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152\u2013169","journal-title":"Pharmacol Ther"},{"issue":"18","key":"1090_CR34","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","volume":"28","author":"D Rischin","year":"2010","unstructured":"Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the trans-Tasman radiation oncology group. J Clin Oncol 28(18):2989\u20132995","journal-title":"J Clin Oncol"},{"issue":"5","key":"1090_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1200\/JCO.2013.51.4265","volume":"32","author":"PA DiSilvestro","year":"2014","unstructured":"DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE et al (2014) Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic oncology group study. J Clin Oncol 32(5):458\u2013464","journal-title":"J Clin Oncol"},{"issue":"8","key":"1090_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL et al (2017) Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 18(8):1089\u20131103","journal-title":"Lancet Oncol"},{"issue":"9","key":"1090_CR37","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-10-3425","volume":"17","author":"GJ Weiss","year":"2011","unstructured":"Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA III (2011) Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 17(9):2997\u20133004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1090_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00280-017-3256-2","volume":"79","author":"RF Riedel","year":"2017","unstructured":"Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI (2017) Phase I study of pazopanib plus TH-302 in advanced solid tumors. Cancer Chemother Pharmacol 79(3):611\u2013619","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 5","key":"1090_CR39","doi-asserted-by":"publisher","first-page":"v10","DOI":"10.1093\/neuonc\/nou237.12","volume":"16","author":"A Brenner","year":"2014","unstructured":"Brenner A, Floyd J, Eng C, Kroll S, Fichtel L, Gruslova A, Lodi A, Tiziani S (2014) AT-12: phase 1\/2 study of TH-302, investigational hypoxia-activated PRODRUG, and BEVACIZUMAB in patients with BEVACIZUMAB-refractory recurrent GLIOBLASTOMA. Neuro-Oncology 16(Suppl 5):v10\u2013vv1","journal-title":"Neuro-Oncology"},{"issue":"11 Supplement","key":"1090_CR40","doi-asserted-by":"crossref","first-page":"B77","DOI":"10.1158\/1535-7163.TARG-13-B77","volume":"12","author":"A Starodub","year":"2013","unstructured":"Starodub A, Vaena D, Pennington KL, Kio EA, Bruetman D, Thorne T et al (2013) Abstract B77: phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib. Mol Cancer Ther 12(11 Supplement):B77","journal-title":"Mol Cancer Ther"},{"issue":"12 Supplement 2","key":"1090_CR41","doi-asserted-by":"crossref","first-page":"IA11","DOI":"10.1158\/1557-3265.AACRAHNS19-IA11","volume":"26","author":"P Jayaprakash","year":"2020","unstructured":"Jayaprakash P, Ai M, Curran MA (2020) Abstract IA11: Reversal of immunotherapy resistance through hypoxia reduction. Clin Cancer Res 26(12 Supplement 2):IA11","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1090_CR42","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103\u20131115","journal-title":"N Engl J Med"},{"issue":"1","key":"1090_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","volume":"21","author":"BI Rini","year":"2020","unstructured":"Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, Verzoni E, Needle MN, McDermott DF (2020) Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol 21(1):95\u2013104","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01090-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01090-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01090-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:06:56Z","timestamp":1678493216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01090-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01090-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-234613\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"none.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study protocol was approved by the institutional review board at each study site. All patients signed an IRB-approved, protocol-specific written informed consent document in accordance with federal and institutional guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}